47 patents
Page 2 of 3
Utility
Method of Treating Refractory Epilepsy Syndromes Using Fenfluramine Enantiomers
30 Dec 21
Methods of treating intractable epilepsy syndromes by administering a therapeutically effective dose of a therapeutic agent consisting essentially of a single fenfluramine enantiomer which can be either levofenfluramine or dexfenfluramine, are provided.
Parthena MARTIN
Filed: 20 Nov 19
Utility
Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same
23 Dec 21
Drug combinations and their use are disclosed.
Stephen J. FARR, Brooks BOYD
Filed: 1 Jul 21
Utility
Compositions and Methods for Treating Seizure-induced Sudden Death
28 Oct 21
5-HT receptor agonists are useful in the treatment of a variety of diseases.
Parthena Martin
Filed: 11 May 18
Utility
Method of Treating Patients with Lennox-gastaut Syndrome
30 Sep 21
A method of treating symptoms of Lennox-Gastaut syndrome in a patient diagnosed with Lennox-Gastaut syndrome, by administering an effective dose of fenfluramine to that patient over a period of time sufficient to reduce or completely eliminate seizures in the patient.
Glenn MORRISON
Filed: 1 Feb 21
Utility
Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same
2 Sep 21
Drug combinations and their use are disclosed.
Stephen J. FARR, BROOKS BOYD
Filed: 19 May 21
Utility
Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
22 Jun 21
Drug combinations and their use are disclosed.
Stephen J. Farr, Brooks Boyd
Filed: 6 Mar 20
Utility
Control System for Control of Distribution of Medication
27 May 21
A system of controlling distribution of a medication in the treatment or prevention of epilepsy is provided.
Richard Alistair Balfour STEWART, Anthony CLARKE
Filed: 8 Feb 21
Utility
Fenfluramine Compositions and Methods of Preparing the Same
20 May 21
Derek J. LONDESBROUGH, Marc W. ANDERSEN
Filed: 27 Jan 21
Utility
Methods of Treating Epileptic Patients with Fenfluramine
13 May 21
The present disclosure provides methods of treating and/or preventing symptoms of epilepsy or epileptic encephalopathy where fenfluramine or a pharmaceutically acceptable salt thereof is or has been administered to a patient or population of patients.
Gail M. Farfel, Thadd Reeder, Parthena M. Martin, Glenn Morrison
Filed: 17 Sep 20
Utility
Method of Treating Epilepsy or Epileptic Encephalopathy with Fenfluramine In Patients without Pulmonary Hypertension
22 Apr 21
Provided herein are methods of identifying a patient population as candidates for effective treatment of symptoms of epilepsy or epileptic encephalopathy with fenfluramine or a pharmaceutically acceptable salt thereof, by pre-selecting patients diagnosed with epilepsy or epileptic encephalopathy, assessing the pre-selected patients for being at risk of or exhibiting symptoms of pulmonary hypertension, treating and re-assessing the selected and treated patients for pulmonary hypertension, and identifying treated and re-assessed patients not exhibiting pulmonary hypertension as candidates for effective treatment of epilepsy or epileptic encephalopathy with fenfluramine or a pharmaceutically acceptable salt thereof.
Brooks M. BOYD, Gail FARFEL
Filed: 3 Jul 19
Utility
Compositions and methods for treating respiratory depression with fenfluramine
23 Mar 21
5-HT receptor agonists are useful in the treatment of a variety of diseases.
Bradley S. Galer, Carl L. Faingold, Parthena Martin
Filed: 22 Nov 19
Utility
Prodrugs of Deoxynucleosides for Treatment of Diseases Cased by Unbalanced Nucleotide Pools
18 Mar 21
Deoxynucleotide prodrugs for treatment of diseases characterized by unbalanced nucleotide pools are provided herein.
Daniel DiPietro
Filed: 12 Apr 19
Utility
Fenfluramine compositions and methods of preparing the same
16 Mar 21
Derek J. Londesbrough, Marc W. Andersen
Filed: 4 Jun 19
Utility
Control system for control of distribution of medication
16 Mar 21
A system of controlling distribution of a medication in the treatment or prevention of epilepsy is provided.
Richard Alistair Balfour Stewart, Anthony Clarke
Filed: 10 Sep 18
Utility
Polymorphic Forms of Deoxycytidine, Compositions Comprising the Same and Uses
25 Feb 21
Polymorphic forms of deoxycytidine and methods for preparing the same are provided herein.
Paul Glidden
Filed: 19 Aug 20
Utility
Compositions and Methods for Treating Respiratory Depression with Fenfluramine
21 Oct 20
5-HT receptor agonists are useful in the treatment of a variety of diseases.
Bradley S. GALER, Carl L. FAINGOLD, Parthena Martin
Filed: 21 Nov 19
Utility
Metabolism Resistant Fenfluramine Analogs and Methods of Using the Same
21 Oct 20
Metabolism-resistant fenfluramine analogs are provided.
Stephen J. FARR, Brooks M. BOYD
Filed: 7 May 20
Utility
Changing Cognitive Function with Fenfluramine
30 Sep 20
Disclosed herein are methods of improving cognitive function in a patient as measured by, for example, improvement in score on a validated scale that measures cognitive function, such as the Behavior Rating Inventory of Executive Function (BRIEF), by administering the test to a patient and obtaining a pre-treatment test score, treating the patient with fenfluramine or its pharmaceutically acceptable salt, and after treatment, re-administering the test of cognitive function to the patient and obtaining a post-treatment score, to allow observation of an improvement in the test score.
Glenn MORRISON, Arnold GAMMAITONI, Brooks M. BOYD
Filed: 7 Oct 19
Utility
Compositions and Methods for Treating Seizure Disorders
23 Sep 20
Functional analogs of fenfluramine are provided.
Parthena MARTIN, Brooks M. BOYD, Arnold GAMMAITONI, Bradley S. Galer, Gail FARFEL
Filed: 21 May 20
Utility
Method of Treating Selected Patient Population Experiencing Dravet Syndrome
2 Sep 20
Provided herein is a method of treating a selected patient population, wherein the patient population is selected based on a determination that the patients have previously been non-responsive when treated with cannabidiol.
Bradley S. GALER, Glenn MORRISON, Brooks M. BOYD
Filed: 10 May 20